Treating refractory leukemias in childhood, role of clofarabine

References

• AladjidiNAuvrignonALeblancTOutcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and ImmunologyJ Clin Oncol20032143778514645428
   PubMed Web of Science ®Google Scholar
• ArceciRJSandeJLangeBSafety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemiaBlood20051061183815886328
   PubMed Web of Science ®Google Scholar
• BaderPHancockJKreyenbergHMinimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALLLeukemia20021616687212200679
   PubMed Web of Science ®Google Scholar
• BonatePLArthaudLCantrellWRJRDiscovery and development of clofarabine:a nucleoside analogue for treating cancerNat Rev Drug Discov200658556317016426
   PubMed Web of Science ®Google Scholar
• BonatePLArthaudLStuhlerJThe distribution, metabolism, and elimination of clofarabine in ratsDrug Metab Dispos2005337394815743978
   PubMed Web of Science ®Google Scholar
• BonatePLCraigAGaynonPPopulation pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemiaJ Clin Pharmacol20044413092215496649
   PubMed Web of Science ®Google Scholar
• BurnettAKKellWJGoldstoneAHThe Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy for AML Improves Disease Free Survival without Extra Toxicity: Preliminary Analysis of 1115 Patients in the MRC AML15 TrialASH Annual Meeting Abstracts200610813
   Google Scholar
• CarsonDAWassonDBEsparzaLMOral antilymphocyte activity and induction of apoptosis by 2-chloro-2’-arabino-fluoro-2’-deoxyadenosineProc Natl Acad Sci USA199289297041348362
   PubMed Web of Science ®Google Scholar
• CastellinoSMAlonzoTABuxtonAOutcomes in childhood AML in the absence of transplantation in first remission-Children’s Cancer Group (CCG) studies 2891 and CCG 213Pediatr Blood Cancer2007124 epub ahead of print
   Web of Science ®Google Scholar
• ChessellsJMRelapsed lymphoblastic leukaemia in children:a continuing challengeBr J Haematol1998102423389695956
   PubMed Web of Science ®Google Scholar
• ChessellsJMVeysPKempskiHLong-term follow-up of relapsed childhood acute lymphoblastic leukaemiaBr J Haematol200312339640514616997
   PubMed Web of Science ®Google Scholar
• Clolar® package insert.
   Google Scholar
• CooperTAyresMNowakBBiochemical modulation of cytarabine triphosphate by clofarabineCancer Chemother Pharmacol200555361815723262
   PubMed Web of Science ®Google Scholar
• Coustan-SmithEGajjarAHijiyaNClinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapseLeukemia20041849950414981525
   PubMed Web of Science ®Google Scholar
• CreutzigUZimmermannMLehrnbecherTLess toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia:results of AML-BFM 98J Clin Oncol200624449950616983120
   PubMed Web of Science ®Google Scholar
• CreutzigUZimmermannMRitterJTreatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trialsLeukemia20051920304216304570
   PubMed Web of Science ®Google Scholar
• CristWMAndersonJRMezaJLIntergroup rhabdomyosarcoma study-IV:results for patients with nonmetastatic diseaseJ Clin Oncol200119309110211408506
   PubMed Web of Science ®Google Scholar
• CrooksGMSatoJKIfosfamide and etoposide in recurrent childhood acute lymphoblastic leukemiaJ Pediatr Hematol Oncol1995173487743235
   PubMed Web of Science ®Google Scholar
• EapenMRaetzEZhangMJOutcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission:a collaborative study of the Children’s Oncology Group and the Center for International Blood and Marrow Transplant ResearchBlood20061074961716493003
   PubMed Web of Science ®Google Scholar
• EckertCBiondiASeegerKPrognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemiaLancet200135812394111675066
   PubMed Web of Science ®Google Scholar
• EinsiedelHGvon StackelbergAHartmannRLong-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87J Clin Oncol20052379425016258094
   PubMed Web of Science ®Google Scholar
• ElionGBHitchingsGHVanderwerffHAntagonists of nucleic acid derivatives. VI. PurinesJ Biol Chem19511925051814907641
   PubMed Web of Science ®Google Scholar
• FaderlSGandhiVKeatingMJThe role of clofarabine in hematologic and solid malignancies – development of a next-generation nucleoside analogCancer2005a10319859515803490
   PubMed Web of Science ®Google Scholar
• FaderlSGandhiVO’BrienSResults of a phase 1–2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemiasBlood2005b105940715486072
   PubMed Web of Science ®Google Scholar
• FaderlSVerstovsekSCortesJClofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or olderBlood2006108455116403905
   PubMed Web of Science ®Google Scholar
• GandhiVKantarjianHFaderlSPharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemiasClin Cancer Res2003963354214695132
   PubMed Web of Science ®Google Scholar
• GandhiVPlunkettWBonatePLClinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia:strategy for treatmentClin Cancer Res20061240111716818700
   PubMed Web of Science ®Google Scholar
• GaynonPSChildhood acute lymphoblastic leukaemia and relapseBr J Haematol20051315798716351633
   PubMed Web of Science ®Google Scholar
• GaynonPSHarrisREAltmanAJBone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy:Children’s Oncology Group study CCG-1941J Clin Oncol2006243150616717292
   PubMed Web of Science ®Google Scholar
• GaynonPSQuRPChappellRJSurvival after relapse in childhood acute lymphoblastic leukemia:impact of site and time to first relapse - the Children’s Cancer Group ExperienceCancer1998821387959529033
   PubMed Web of Science ®Google Scholar
• GeniniDAdachiSChaoQDeoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondriaBlood20009635374311071652
   PubMed Web of Science ®Google Scholar
• GibsonBEWheatleyKHannIMTreatment strategy and long-term results in paediatric patients treated in consecutive UK AML trialsLeukemia2005192130816304572
   PubMed Web of Science ®Google Scholar
• GouldenNBaderPVan Der VeldenVMinimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemiaBr J Haematol200312224912823342
   PubMed Web of Science ®Google Scholar
• GrovasAFremgenARauckAThe National Cancer Data Base report on patterns of childhood cancers in the United StatesCancer1997802321329404710
   PubMed Web of Science ®Google Scholar
• HijiyaNFranklinJRyttingMA phase I study of clofarabine in combination with cyclophosphamide and etoposide:a new regimen in pediatric patients with relapsed or refractory acute leukemiaProc Am Soc Clin Oncol200726 abstract #9529
   Google Scholar
• HitchingsGHElionGBFalcoEAStudies on analogs of purines and pyrimidinesAnn N Y Acad Sci19505213183515433149
   PubMed Web of Science ®Google Scholar
• IqbalSLenzHJIntegration of novel agents in the treatment of colorectal cancerCancer Chemother Pharmacol200454Suppl 1S323915309512
   PubMed Web of Science ®Google Scholar
• JehaSGandhiVChanKWClofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemiaBlood2004103784914551141
   PubMed Web of Science ®Google Scholar
• JehaSGaynonPSRazzoukBIPhase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemiaJ Clin Oncol2006a2419172316622268
   PubMed Web of Science ®Google Scholar
• JehaSKantarjianHClofarabine for the treatment of acute lymphoblastic leukemiaExpert Rev Anticancer Ther2007711311817288522
   PubMed Web of Science ®Google Scholar
• JehaSRazzoukBGaynonPClofarabine in children with refractory/relapsed acute leukemia: results of 2 phase ii open label studiesASH Annual Meeting Abstracts2006b1084460
   Google Scholar
• JemalATiwariRCMurrayTCancer statistics, 2004CA Cancer J Clin20045482914974761
   PubMed Web of Science ®Google Scholar
• KantarjianHGandhiVCortesJPhase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemiaBlood2003a10223798612791647
   PubMed Web of Science ®Google Scholar
• KantarjianHMGandhiVKozuchPPhase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancersJ Clin Oncol2003b2111677312637486
   PubMed Web of Science ®Google Scholar
• KantarjianHJehaSGandhiVClofarabine:Past, present, and futureLeuk Lymphoma200781319 epub ahead of print17325839
   PubMed Web of Science ®Google Scholar
• KearnsPMichelGNelkenBBIOV-111a European phase II trial of clofarabine (Evoltra) in refractroy and relapsed childhood acute lymphoblastic leukemiaBlood2006108527a abstract #1859
   Web of Science ®Google Scholar
• KnechtliCJGouldenNJHancockJPMinimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemiaBlood199892407299834212
   PubMed Web of Science ®Google Scholar
• KurtzbergJThe long and winding road of the clinical development of NelarabineLeuk Lymphoma2007481217325839
   PubMed Web of Science ®Google Scholar
• LevisMSmithBDBeranMA randomized, open-label study of lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibitionASH Annual Meeting Abstracts2005106403
   Google Scholar
• MiserJSKinsellaTJTricheTJIfosfamide with mesna uroprotection and etoposide:an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adultsJ Clin Oncol19875119183114435
   PubMed Web of Science ®Google Scholar
• NguyenKChengS-CRaetzEFactors influencing survival after relapse from childhood ALL: A Children’s Oncology Group studyASH Annual Meeting Abstracts20061081855
   Google Scholar
• ParkerWBShaddixSCChangCHEffects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5’-triphosphateCancer Res1991512386941707752
   PubMed Web of Science ®Google Scholar
• ParkerWBShaddixSCRoseLMComparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2- fluoro-beta-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro- beta-D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro- beta-D-ribofuranosyl)adenine in CEM cellsMol Pharmacol1999555152010051535
   PubMed Web of Science ®Google Scholar
• PlunkettWGandhiVPurine and pyrimidine nucleoside analogsCancer Chemother Biol Response Modif200119214511686015
   PubMedGoogle Scholar
• PollardJAAlonzoTAGerbingRBFLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemiaBlood20061082764916809615
   PubMed Web of Science ®Google Scholar
• PowellBLMoserBStockWPreliminary results from the North American Acute Promyelocytic Leukemia (APL) study C9710ASH Annual Meeting Abstracts2006108566
   Google Scholar
• PowellBMoserBStockWEffect of consolidation with arsenic trioxide (As 2 O 3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL):North American Intergroup Protocol C9710Proc Am Soc Clin Oncol2007262
   Google Scholar
• PuiCHJehaSClofarabineNat Rev Drug Discov2005bSupplS1213
   PubMedGoogle Scholar
• PuiCHJehaSKirkpatrickPClofarabineNat Rev Drug Discov2005a43697015902772
   PubMed Web of Science ®Google Scholar
• RaetzEABorowitzMJDevidasMOutcomes of children with first marrow relapse: Results from Children’s Oncology Group (COG) study AALL01P2ASH Annual Meeting Abstracts20061081871
   Google Scholar
• ReinhardtDDiekampSFleischhackGGemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemiaOnkologie2004272697215249716
   PubMed Web of Science ®Google Scholar
• ScheinPSThe case for a new national program for the development of cancer therapeuticsJ Clin Oncol20011931425311408512
   PubMed Web of Science ®Google Scholar
• SchultzKRPullenDJSatherHNRisk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia:a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG)Blood20071099263517003380
   PubMed Web of Science ®Google Scholar
• SieversELLarsonRAStadtmauerEAEfficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapseJ Clin Oncol20011932445411432892
   PubMed Web of Science ®Google Scholar
• SkipperHEThomsonJRElionGBObservations on the anticancer activity of 6-mercaptopurineCancer Res195414294813160953
   PubMed Web of Science ®Google Scholar
• TallmanMSNew agents for the treatment of acute myeloid leukemiaBest Pract Res Clin Haematol2006193112016516128
   PubMed Web of Science ®Google Scholar
• WebbDKManagement of relapsed acute myeloid leukaemiaBr J Haematol1999106851910519984
   PubMed Web of Science ®Google Scholar
• WellsRJAdamsMTAlonzoTAMitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children’s Cancer Group Study 2951J Clin Oncol2003212940712885813
   PubMed Web of Science ®Google Scholar
• XieCPlunkettWMetabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)-adenine in human lymphoblastoid cellsCancer Res1995552847527540950
   PubMed Web of Science ®Google Scholar
• XieKCPlunkettWDeoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenineCancer Res199656303078674058
   PubMed Web of Science ®Google Scholar
• YamauchiTNowakBJKeatingMJDNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabineClin Cancer Res200173580911705880
   PubMed Web of Science ®Google Scholar
• ZwaanCMReinhardtDCorbaciogluSGemtuzumab ozogamicin:first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basisBlood200310138687112543868
   PubMed Web of Science ®Google Scholar